Literature DB >> 15245490

TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.

Devi R Sagar1, Paul A Smith, Paul J Millns, Darren Smart, David A Kendall, Victoria Chapman.   

Abstract

N-arachidonoyl-dopamine (NADA) is an endogenous ligand at TRPV1 and CB(1) receptors, which are expressed on primary afferent nociceptors. The aim of this study was to determine contributions of proposed pronociceptive TRPV1 and antinociceptive CB(1) receptors to effects of peripheral NADA on primary afferent fibre function. Effects of NADA on primary afferent nociceptor function, determined by whole cell patch clamp and calcium imaging studies of adult dorsal root ganglion (DRG) neurons, were determined. Application of NADA (1 microm) to DRG neurons depolarized the resting membrane potential (Vm) from -58 +/- 1 to -44 +/- 3 mV (P < 0.00001) and evoked a significant increase (P < 0.0001) in intracellular calcium (74 +/- 11% of response to 60 mm KCl), compared to basal. The TRPV1 receptor antagonist capsazepine abolished NADA-evoked depolarization of Vm (P < 0.0001) and NADA-evoked calcium responses (P < 0.001), which were also blocked by the CB(1) receptor antagonist SR141716A (P < 0.001). Effects of NADA (1.5 microg and 5 microg/50 microL) on mechanically evoked responses of dorsal horn neurons in anaesthetized Sprague-Dawley rats were studied. Intraplantar injection of the higher dose of NADA (5 microg/50 microL) studied significantly inhibited innocuous (8, 10 g) mechanically evoked responses of dorsal horn neurons compared to vehicle, effects blocked by intraplantar injection of SR141716A. Higher weight (26-100 g) noxious-evoked responses of dorsal horn neurons were also significantly inhibited by NADA (5 microg/50 microL), effects blocked by intraplantar injection of the TRPV1 antagonist, iodo-resiniferatoxin. NADA has a complex pattern of effects on DRG neurons and primary afferent fibres, which is likely to reflect its dual site of action at TRPV1 and CB(1) receptors and the differential expression of these receptors by primary afferent fibres.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245490     DOI: 10.1111/j.1460-9568.2004.03481.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  16 in total

1.  N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1.

Authors:  Samira K Lawton; Fengyun Xu; Alphonso Tran; Erika Wong; Arun Prakash; Mark Schumacher; Judith Hellman; Kevin Wilhelmsen
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

Review 2.  Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

Review 3.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.

Authors:  Mayur Patil; Amol Patwardhan; Margaux M Salas; Kenneth M Hargreaves; Armen N Akopian
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

5.  The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin.

Authors:  Amol M Patwardhan; Nathaniel A Jeske; Theodore J Price; Nikita Gamper; Armen N Akopian; Kenneth M Hargreaves
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

6.  Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors.

Authors:  N Rimmerman; H B Bradshaw; A Basnet; B Tan; Theodore S Widlanski; J M Walker
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-02       Impact factor: 3.072

7.  The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine.

Authors:  Sherry Shu-Jung Hu; Heather B Bradshaw; Valery M Benton; Jay Shih-Chieh Chen; Susan M Huang; Alberto Minassi; Tiziana Bisogno; Kim Masuda; Bo Tan; Robert Roskoski; Benjamin F Cravatt; Vincenzo Di Marzo; J Michael Walker
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-06-30       Impact factor: 4.006

8.  The group IV afferent neuron expresses multiple receptor alterations in cardiomyopathyic rats: evidence at the cannabinoid CB1 receptor.

Authors:  Maurice A Williams; Scott A Smith; Daniel E O'Brien; Jere H Mitchell; Mary G Garry
Journal:  J Physiol       Date:  2007-12-06       Impact factor: 5.182

9.  Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.

Authors:  Hamish R Ross; Andrew J Gilmore; Mark Connor
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

10.  The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.

Authors:  Kevin Wilhelmsen; Samira Khakpour; Alphonso Tran; Kayla Sheehan; Mark Schumacher; Fengyun Xu; Judith Hellman
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.